September 23rd, 2010
Fondaparinux Effective in Superficial-Vein Thrombosis
Larry Husten, PHD
In the randomized, double-blind CALISTO (Comparison of Arixtra in Lower Limb Superficial Vein Thrombosis with Placebo) trial, 3002 patients with acute, symptomatic superficial-vein thrombosis in the legs, but without DVT or symptomatic PE, received either fondaparinux (2.5 mg) or placebo for 45 days. The primary efficacy endpoint ─ a composite of all-cause death, symptomatic PE […]
August 31st, 2010
Positive Results for Rivaroxaban in EINSTEIN-DVT
Larry Husten, PHD
The EINSTEIN-DVT study tested the effect of the new oral anticoagulant rivaroxaban in the setting of DVT. The open-label, non-inferiority study randomized more than 3,400 patients with acute, symptomatic DVT to either oral rivaroxaban or conventional therapy with enoxaparin followed by warfarin or acenocoumarol for 3, 6, or 12 months, based on the attending physician’s […]
NEJM Journal Watch — Recent Cardiology Articles- To Lower Stroke Risk in Patients Undergoing Atrial Fibrillation Ablation, Is a Device or a Medication Better?
- Intensive vs. Standard Blood Pressure Lowering in Patients with Diabetes
- Anticoagulation in Patients with Cancer-Associated Pulmonary Embolism: How Long is Long Enough?
- Spironolactone Use After Percutaneous Intervention for Acute Myocardial Infarction
- CRISPR/Cas9 Gene Editing for Transthyretin Cardiomyopathy